Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis SurveyNicola Silvestris, Daniele Santini, Francesco Pantano et al.|PLoS ONE|2013Cited by 67
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO FoundationSara Lonardi, M. Frisinghelli, Cosimo Rasola et al.|Journal of Clinical Oncology|2023Cited by 41
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Filippo Pietrantonio, Rossana Berardi et al.|BMC Cancer|2019Cited by 15
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 studyRoberto Moretto, Chiara Cremolini, Mirella Giordano et al.|European Journal of Cancer|2021Cited by 7